Prevalence of Alpha-1 Antitrypsin Dysfunction in Pulmonary Emphysema
Information source: Hospices Civils de Lyon
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Pulmonary Emphysema
Intervention: Blood sampling (Other)
Phase: N/A
Status: Recruiting
Sponsored by: Hospices Civils de Lyon Overall contact: Jean-François MORNEX, MD, PhD, Phone: +33 4 72 35 72 89, Email: jean-francois.mornex@chu-lyon.fr
Summary
The main objective of this trial is to evaluate the prevalence of alpha-1 antitrypsin
quantitative and functional deficiency in an adult French population presenting with
pulmonary emphysema. Phenotypic and genotypic studies will be carried whenever quantitative
and/or functional deficiency will be displayed.
Clinical Details
Study design: Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Primary outcome: Number of patient with alpha-1 antitrypsin dysfunction
Secondary outcome: Determination of alpha-1 antitrypsin protein phenotypeMolecular genotyping of gene coding alpha-1 antitrypsin
Eligibility
Minimum age: 18 Years.
Maximum age: 80 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Pulmonary emphysema highlighted by computed tomography
- Ratio Forced Expiratory Volume in 1 second (FEV1) / Vital Capacity (VC) < 70%
measured by lung function test
Exclusion Criteria:
- Hepatic transplant
- Patient under legal protection
- Patient not benefiting from the French Health Insurance
Locations and Contacts
Jean-François MORNEX, MD, PhD, Phone: +33 4 72 35 72 89, Email: jean-francois.mornex@chu-lyon.fr
Hôpital Louis Pradel - service de pneumologie, Bron 69677, France; Recruiting Jean-François MORNEX, MD, PhD, Phone: +33 4 72 35 72 89, Email: jean-francois.mornex@chu-lyon.fr Bernadette VAZ, CRA, Phone: +33 4 27 85 53 26, Email: Bernadette.vaz@chu-lyon.fr Jean-François MORNEX, MD, PhD, Principal Investigator
Additional Information
Starting date: December 2014
Last updated: May 26, 2015
|